Sana Biotechnology

Sana Biotechnology, Inc. (SANA) focuses on engineered cells as medicines, targeting oncology, diabetes, CNS disorders, and autoimmune diseases. With a market cap of $1.116B, it develops therapies like SC291 for hematologic malignancies and SC451 for diabetes. Sana collaborates with Beam Therapeutics and Harvard College for cell therapy advancements.

Morgan Stanley increased Sana Biotechnology's price target to $12 from $9, maintaining an Overweight rating. The firm raised SC451's success probability to 20% following a type one diabetes update and anticipates hypoimmune pipeline updates through 2025. UP421 update was positively noted for safety, C-peptide levels, and cell survival.

HC Wainwright raised Sana Biotechnology's target price to $11, maintaining a buy rating. Analysts' ratings vary, with an average 'Moderate Buy' and target price of $14.25. Sana's stock opened at $3.66, with a market cap of $817.16M. Insiders and hedge funds have adjusted their stakes, with institutional investors owning 88.23%.

Morgan Stanley's Vikram Purohit maintains a Buy rating on Sana Biotechnology (SANA) with a $9.00 target, despite a $59.92M Q3 loss. Shares opened at $2.60. The Street consensus is a Moderate Buy with a $10.67 target, indicating a 310.38% upside. SANA develops engineered cell therapies.

Sana Biotechnology insider Fmr Llc sold 290,912 shares at $6.49 each, totaling $1,888,018.88, reducing their stake by 6.02%. SANA stock opened at $3.66, with a market cap of $817.16M. Analysts have mixed ratings, with a consensus of 'Moderate Buy' and an average target price of $14.25. Institutional investors hold 88.23% of SANA, with several increasing their stakes recently. Sana Biotechnology focuses on engineered cells for therapeutic areas with unmet needs.

AMD partners with Absci for AI drug discovery, investing $20M. Despite this, AMD's stock fell due to a downgrade by HSBC, citing Nvidia's dominance in GPUs. Nvidia continues to expand in life sciences, contrasting with AMD's challenges in the AI GPU market.

Sana Biotechnology, Inc. focuses on engineered cells as medicines for various therapeutic areas. With a Moderate Buy consensus rating, its stock has seen significant volatility, trading between $1.52 and $12.00 over the past year. The company, headquartered in Seattle, Washington, has a market capitalization of $960.06 million and is developing several product candidates for diseases like cancer and diabetes.

Fmr Llc sold 290,912 Sana Biotechnology shares at $6.49 each, totaling $1,888,018.88, reducing their stake by 6.02%. SANA's stock closed at $3.66, with a market cap of $817.16M. Analysts rate it 'Moderate Buy' with a $14.25 target. Hedge funds adjusted stakes, owning 88.23% of SANA, focusing on engineered cells for therapeutic areas.

FMR LLC sold $1.89M worth of Sana Biotechnology shares, reducing its indirect holdings to 4,541,511 shares. SANA's stock surged 151% last week, with a market cap of $810M. Sana's HIP technology shows promise in treating Type 1 diabetes without immunosuppressants. FDA granted SC291 Fast Track designation. Leadership changes include CFO Nathan Hardy's 2024 departure and Dhaval Patel's appointment as CSO.

FMR LLC sold $1.89M worth of Sana Biotechnology shares, reducing its stake to 4,541,511 shares. SANA's stock showed a 151% gain recently, with a market cap of $810M. Sana Biotechnology advances in HIP technology for type 1 diabetes treatment, receiving FDA Fast Track for SC291. Leadership changes include Nathan Hardy stepping down as CFO and Dhaval Patel appointed as CSO.